In 2024, the US Food and Drug Administration (FDA) approved benzgalantamine delayed-release tablets (Zunveyl®), a cholinesterase inhibitor with an FDA indication “for the treatment of mild to moderate dementia of the Alzheimer’s type in adults”. (Yes, the official FDA indication specifies that benzgalantamine is only approved for use in adults for the treatment of mild…